Ministry of Health of the Republic of Armenia Feb 2013.

Slides:



Advertisements
Similar presentations
PRECURSOR CHEMICALS.
Advertisements

Vienna, Austria 4 September 2014 Stefano Berterame, Chief Narcotics Control and Estimates Section Secretariat of the International Narcotics Control Board.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.
Introduction to Treat the Pain. The problem of unrelieved pain Globally, 7.3 million people die of cancer or HIV each year in moderate or severe pain.
1 Potential & Actual Opioid Diversion in Vietnam, Methods of Preventing Diversion, and Barriers to “Balance” Eric Krakauer, MD, PhD Harvard Medical School.
CDER/CSS ALSDAC September 9-10, 2003 Risk Management and the Controlled Substances Act: The FDA Perspective Deborah B. Leiderman, M.D., M.A. Director Controlled.
Bylaw on drug demand reduction in Serbia. Bylaw(s) - principles  should be based on existing law(s)  should complement existing laws  should not be.
Improving access to opioid analgesics: Ukraine March 5-6, 2013 Vienna.
PSK Annual Conference 2008 Palliative care medicine: A balanced approach to opioid availability and safe use in Kenya Presenter: Dr. Bilha Kiama-Murage.
1 Description of the addiction service of the Republic of Uzbekistan Jur’at Umargaliev Ministry of Health.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
Procedure for narcotic drugs use for medical purposes in the Republic of Kazakhstan.
Situation analysis in Kyrgyzstan Making Opioids Available in Eastern Europe and Central Asia March 5-6, 2013 Vienna.
Municipal Drug Policy Legislation, institutions and programs Assoc. Prof. Hristo Bozov, MD, PhD Deputy-Mayor of Municipality of Varna Chairman of Municipal.
California State Board of Pharmacy Continuing Education Program Senate Bill 151 (Burton)
Richard Z Aramini, PharmD PGY-1 Pharmacy Practice Resident Bay Pines VA Healthcare Center.
Association of Pharmaceutical Companies Representatives in Georgia APCRG, WASHINGTON DC, February
REGIONAL HEALTHCARE CENTER ASSOC. PROF. D-R PETKO SALCHEV PhD.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA. Presentation by: Dr. Joseph K. Yano B.Pharm (Nbi) L.L.B (Moi) Legal Officer Pharmacy and Poisons Board Ministry.
Research Activities to Document Progress During IPPF Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist Pain & Policy Studies Group.
1 Accessibility of Opioids in the Republic of Kazakhstan G.U. Raimkulova – Head of Pharmaceutical Activities Administration, Medical and Pharmaceutical.
Country Report for: UKRAINE Natallia Datsiuk, MPH Bogomolets National Medical University Ukraine, Kyiv.
For Pain or Not for Pain: Methadone Madness
Current System of Drug Control In Georgia Prof. D. Kordzaia – Georgian National Association for Palliative Care VIENNA - March 5-6, 2013 “Making Oral Opioids.
“Improving opioid availability through advocacy” Experience from Serbia Snežana Bošnjak International Pain Policy Fellow ( ) Institute for Oncology.
IAEA REGULATION RADIOACTIVE MATERIALS TRANSPORTATION IN ARMENIA Ashot Mnatsakanyan Head of Radiation Safety Department Armenian Nuclear Regulatory Authority.
WHO Access to Controlled Medications Programme & Ensuring balance in national policies on controlled substances Barbara Milani, Technical Officer Department.
Overviews of the Drug Distribution System & Barriers to Opioid Availability Dr. Bishnu Dutta Paudel International Pain Policy Fellowship Training Program.
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
Twinning Project SR 10 IB JH 02 Twinning Project SR 10 IB JH 02 Implementation of Strategy for Fight Against Drugs (Supply and Demand Reduction Component)
Description of the current system of drug control in Romania Prof. Daniela Mosoiu, MD, PhD Hospice Casa Sperantei Brasov, Romania.
OR “READ THE FINE PRINT PLEASE!”
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Country Report for:
ACCESS TO MEDICINES - POLICY AND ISSUES
Projection of Psychiatry services By the year 2000 Project Objectives Continue to offer psychiatric services within  The Primary Health Care Services.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
Tajikistan Making Opioids Available in Eastern Europe and Central Asia March 5-6, 2013 Vienna.
Methods to Evaluate and Improve National Policy: Focus on 2011 WHO Guidelines and PPSG Global Policy Evaluation Aaron M. Gilson, MS, MSSW, PhD Research.
Meg O’Brien, Ph.D. Director, Global Access to Pain Relief Initiative Procurement & Manufacture of IR Oral Morphine: Uganda experience 1.
Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade.
Ensuring Availability and Preventing Diversion International Pain Policy Fellowship August 7, 2012 David E. Joranson University of Wisconsin Pain & Policy.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Cohort III International.
Dean R Hatt. Famous Quotes  “Drug misuse is not a disease, it is a decision, like the decision to step out in front of a moving car. You would call.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
STRENGTHENING NATIONAL INFRASTRUCTURES FOR THE CONTROL OF RADIATION SOURCES RER/9/096 REGIONAL PLANNING MEETING ARMENIA ASHOT MNATSAKANYAN Head of Radiation.
Preventing drug diversion: Principles and concepts International Pain Policy Fellowship August 7, 2012 David E. Joranson Distinguished Scientist, Founder.
Unit 5. THE ORGANIZATION OF PRESCRIPTION DEPARTMEN PHARMACY. RULES OF EXCERPTION AND RECEPTION OF RECIPE.
1 M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 29 – Customs union Bilateral screening:
Prescription Drug Monitoring Presented by: Len Abbott, Ph.D. Director Science and Technology Kathleen Valentine, General Manager PDM & Toxicology May 14,
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Pennsylvania's Prescription Drug Monitoring Program (PDMP) May 17, 2016.
Understanding Drug Labels
Medication Assisted Treatment
Director, Environmental Assessment & Control Directorate
CDA PRESENTATION TO PORTFOLIO COMMITTEE ON SOCIAL DEVELOPMENT 2005/03/09 PROF RATAEMANE.
New developments in alcohol and drug policy of the Russian Federation
Bilateral screening: Chapter 1
Change in legislation on alcohol, tobacco and drugs in Russia in 2016.
ROOM project Addressing the Opioid Epidemic in the U.P.
11/18/2018 What is NDS? A Management Information System (MIS) for national and international drug control Automates range of day-to-day drug control.
Federal Regulations requirements for opioid prescription course
Indispensable, adequately provided and not unduly restricted
Prescription Drug Monitoring Program
Director, Environmental Assessment & Control Directorate
INCB PERMITS & REQUIREMENTS FOR ESTIMATES.
Prescription Drug Monitoring Program
National Credentialing Forum 2019 San Diego, CA February
بسم الله الرحمن الرحيم Dr. Hany Sallam & Regulatory Activities
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA
Situation analysis in Kyrgyzstan
GMP Legal Framework in Kyrgyzstan
Presentation transcript:

Ministry of Health of the Republic of Armenia Feb 2013

O pioid analgesics registered in the Republic of Armenia NameDosage, Prescription Form Producing country, Company Registration Date Valid to 1.Morphine hydrochloride 1% solution for infusion 10 mg/ml; (100/20x5/) 1 ml ampoule “Zdorovye narodu” OJSC, Ukraine Omnopon-ZN (Morphine hydrochloride, papaverine hydrochloride, codeine, noscapine, tebaine) 11,5 mg/ml + 0,72 mg/ml +1,44 mg/ml + 5,4 mg/ml + 0,1 mg/ml ; (100/20x5/) 1 ml ampoule “Zdorovye narodu” OJSC, Ukraine Fentanyl 0.005%, solution for infusion 0,05 mg/ml ; (100/20x5/) 2 ml ampoule “Zdorovye narodu” OJSC, Ukraine Promedol- ZN(trimetoperidine hydrochloride) 20 mg/ml (100/20x5/) 1 ml ampoule “Zdorovye narodu” OJSC, Ukraine

NameDosage, Prescription Form Producing country, Company Registration Date Valid to 5. Durogesic Matrix 25mcg/h TDTS, 4,2 mg, 5 in a box Alza Ireland Ltd, Janssen Pharmaceutica l N.V Durogesic Matrix 50 mcg/h TDTS, 8,4 mg, 5 in a box Alza Ireland Ltd, Janssen Pharmaceutica l N.V Methadose™ Oral Tablets (methadone hydrochloride) Tablets, USP 5 mg, bottles of 100 tablets Mallinckrodt Inc., USA Methadose™ Oral Tablets (methadone hydrochloride) Tablets, USP 10 mg; bottles of 100 tablets Mallinckrodt Inc., USA Methadose™ Oral Tablets (methadone hydrochloride) Tablets, USP 40 mg; bottles of 100 tablets Mallinckrodt Inc., USA O pioid analgesics registered in the Republic of Armenia

NameDosage, Prescription Form Producing country, Company Registrati on Date Valid to 6 Tramadol, solution for injection 100 mg /2 ml; (5) ampoules 2 ml CRCA, Novo Mesto, Slovenia Tramadol, capsules 50 mg (20/2x10/) blisters CRCA, Novo Mesto, Slovenia Tramadol-M 50 mg/ml (1 ml);1 ml ampoules (10) “Zororvye narodu” OJSC, Ukraine Tramadol-M 50 mg/ml (2ml) 2 ml ampoules (5) “Zororvye narodu” OJSC, Ukraine Tramadol, solution for injection 100 mg/2 ml; (5) ampoules 2 մլ Hemopharm AD - Serbia Tramadol 50 մ mg (20/2x10/) blistersHemopharm AD - Serbia Tramadol Alcaloid, capsules 50 mg; (20) in bottlesAlcaloid AD - Skopje Tramadol Alcaloid, solution for injection 50 մգ / մլ ; (5) ampoules 2 ml Alcaloid AD - Skopje O pioid analgesics registered in the Republic of Armenia

Armenia is not a major drug-producing country and because of conservative social mores domestic abuse of drugs is relatively modest; Some use (secondary route) as a transit country for drug trafficking; Opiates, are the second most abused drug group (after hashish and cannabis) ; In 2009 Armenia implemented new legislation towards EU standards, decriminalization of the use of illegal drugs (emphasizing prevention & treatment of drug users) and adopted a three year national drug strategy; In 2011 the Monitoring Centre for Narcotic Drugs and Drug Addiction was established under the National Institute of Health; Armenia is a party to the 1988 UN Drug Convention. R egulation of Drug Circulation In Armenia

International treaties - UN Single Convention on Narcotic Drugs of UN Convention on Psychotropic substances of UN Convention against Illicit traffic in Narcotic Drugs and Psychotropic Substances f 1988 Domestic Regulatory documents - The Law of the Republic of Armenia on the Narcotic & Psychotropic Substances (Dec 26, 2002), The Law on Pharmaceuticals - Decrees of the Government on licensing of agencies on drugs importation, exportation, production, warehousing, and distribution: on lists of controlled drugs and their precursors and on the order of their circulation, decree of the MoH on prescriptions, etc

R egulation of Drug Circulation In Armenia Agencies involved - The Government of Armenia (approves the lists of controlled drugs and their precursors, their circulation order and annual quotes for the Armenia) -Ministry of Health of Armenia (responsible for registration and licensing) - Police Department at the Government of Armenia -Customs Service -National Security Service -Prosecutor’s Office

T esting and registration, importation, warehousing, distribution, storage, prescribing, dispensing, monitoring of prescription usage Testing and registration of narcotic drugs is not different from other pharmaceuticals. - Testing is done at the laboratory of the Drug Expertise Center of the MoH - Registration is done by the MoH - Activities of importation, warehousing, distribution of narcotics should be licensed by the Ministry of Health (special condition requirements). Currently only one organization “Armpharmacia” JSC, holds the license for importation and warehousing of narcotics. - Dispensing of narcotics is done through prescriptions by the order of prescriptions and distribution of pharmaceuticals approved by the Ministerial decree #100 of Feb 26, 2002 on the order using prescription form #1 approved by the Government of Armenia (forms 2 and 4 are used for psychotropic substances). - Monitoring of narcotic drugs dispensing and usage in pharmacies and health care institutions is done by the Ministry of Health. - Annual reports on narcotics circulation are submitted to the MoH and Police Dept by institutions licensed for circulation of narcotic drugs.

R estrictions on prescribing, i.e. route of administration, dose, length of prescription? The acting Law on narcotics does not stipulate a special procedure and condition of the use of narcotics/psychotropic substances for medical purposes. Only One opioid or psychotropic substance may be prescribed at each prescription form Prescription of narcotics in out-patient facilities is only available to cancer patients (morphine injectable form only) Prescriptions of narcotic drugs are issued for 2 days (Prescriptions of narcotic and psychotropic drugs is valid for 20 days). The process of prescription is cumbersome (through a decision of a committee, each prescription to be validated by signature and personal stamp of the prescribing physician, the prescription stamp, the signature and stamp of the director or deputy director and round seal of the facility).

M ain activities carried out in Armenia in towards development of palliative care (in cooperation with the GF and OSF) Situational analysis, draft guidelines in pain management and national guidelines on palliative care developed Pilot testing of different models of palliative care in four sites implemented and in progress patients included home visits, 1388 out-patient vists and 4697 emergency calls served. - Regulated by Ministerial decree the patients enrolled in pilots receive methadone procured under the GF funded HSS project.

E xpert assessment of the oral morphine requirement for Armenia Assumptions: -Current usage of morphine is Kg for injectable only - Oral morphine will replace 75% of the injectable and we need more mg for oral than injectable - Estimated 25% increase annually due to education and pilot projects Estimates: kg (2.475 kg oral, inj.) kg (3.11 kg oral, 1.04 kg inj.) (3.89 kg oral, 1.3 kg inj.)

W hat is the projected need for morphine in the country by dosage form (IR, SR, and injectable) The quotes of narcotic and psychotropic medication to be produced, imported to or exported from the Republic of Armenia are implemented by the Government of RA. Quotes of 2013: - Morphine (all forms) g - Codeine – 3000 g - Phentanyl (all forms)-21 g - Methadone (all forms) g - Tebaine --10g, Trimetoperidine g

A ctivities foreseen for 2013 Registration of oral morphine (included in the list of essential medicines of low demand) is underway Pilot projects continue, evaluation expected end of 2013 Comprehensive review of legislation on narcotic drugs aimed at improved conditions and increased availability of opioid analgesics for patients in need in Armenia. THANK YOU!!!